FrancophonIA/ELRC3.0 huggingface dataset:
English: Due to the possibility of a reduction of the therapeutic effect of bedaquiline due to a decrease in systemic exposure, co-administration of bedaquiline and moderate or strong CYP3A4 inducers (e.g. efavirenz, etravirine, rifamycins including rifampicin, rifapentine and rifabutin, carbamazepine, phenytoin, St. John's wort (Hypericum perforatum)) used systemically should be avoided.
Slovenian: Zaradi zmanjšanja sistemske izpostavljenosti zdravilu lahko pride do zmanjšanja terapevtskega učinka bedakilina, zato se je treba izogibati sočasni uporabi bedakilina in zmernih ali močnih induktorjev encima CYP3A4 (npr. efavirenz, etravirin, rifamicini (vključno z rifampicinom, rifapentinom in rifabutinom), karbamazepin, fenitoin, šentjanževka (Hypericum perforatum)) s sistemskim vnosom.
English: Furthermore, response rates in patients that completed the bedaquiline treatment period were comparable between different race categories in the clinical trials.
Slovenian: Razen tega je bil v kliničnih študijah delež bolnikov z odzivom med bolniki, ki so zaključili obdobje zdravljenja z bedakilinom, med različnimi rasnimi kategorijami primerljiv.
English: CYP3A4 is the major CYP isoenzyme involved in vitro in the metabolism of bedaquiline and the formation of the N-monodesmethyl metabolite (M2).
Slovenian: Encim CYP3A4 je najpomembnejši izoencim CYP, ki je vpleten v in vitro presnovo bedakilina in tvorbo N-monodesmetilnega presnovka (M2).
English: Purpose of the medicine rifampicin, rifapentine, rifabutin to treat some infections like tuberculosis (antimycobacterial)
Slovenian: Zakaj se zdravilo uporablja rifampicin, rifapentin, rifabutin za zdravljenje okužb, kot je tuberkuloza (zdravila za zdravljenje okužb z mikobakterijami)
English: Elderly population (≥ 65 years of age) There is limited clinical data (n = 2) on the use of SIRTURO in elderly patients.
Slovenian: Starejši bolniki (≥ 65 let) Kliničnih podatkov o uporabi zdravila SIRTURO pri starejših bolnikih je zelo malo (n = 2).
English: • Take 200 mg (2 tablets of 100 mg) once a day for 3 days of each week only.
Slovenian: • jemljete 200 mg (2 tableti po 100 mg) enkrat na dan samo 3 dni v tednu.
English: Bedaquiline and M2 were not substrates of P-gp in vitro.
Slovenian: Bedakilin in M2 in vitro nista bila substrata P-gp.
English: Bedaquiline and M2 are not substrates or inhibitors of P-glycoprotein.
Slovenian: Bedakilin in presnovek M2 nista substrata ali zaviralca glikoproteina P.
English: In a placebo-controlled clinical study in patients with multi-drug resistant Mycobacterium tuberculosis, no major impact of co-administration of bedaquiline on the pharmacokinetics of ethambutol, kanamycin, pyrazinamide, ofloxacin or cycloserine was observed.
Slovenian: V s placebom nadzorovani klinični študiji z bolniki, ki so imeli okužbo z bakterijo Mycobacterium tuberculosis odporno proti več zdravilom, niso opazili bistvenega vpliva sočasne uporabe bedakilina na farmakokinetiko etambutola, kanamicina, pirazinamida, ofloksacina ali cikloserina.
English: Therefore, the combination of bedaquiline and moderate or strong CYP3A4 inhibitors used systemically for more than 14 consecutive days should be avoided.
Slovenian: Zato se je treba izogibati sočasni uporabi bedakilina in zmernih oziroma močnih zaviralcev encima CYP3A4 s sistemskim vnosom, ki bi trajala več kot 14 zaporednih dni.
English: However, in patients with severe renal impairment (creatinine clearance < 30 ml/min) or end-stage renal disease requiring haemodialysis or peritoneal dialysis, bedaquiline concentrations may be increased due to alteration of active substance absorption, distribution, and metabolism secondary to renal dysfunction.
Slovenian: Pri bolnikih s hudo okvaro ledvic (očistek kreatinina < 30 ml/min) ali s končno ledvično odpovedjo, zaradi katere je potrebno zdravljenje s hemodializo ali peritonealno dializo, lahko pride do zvišanja koncentracij bedakilina zaradi spremenjene absorpcije, porazdelitve in presnove učinkovine pri zmanjšani ledvični funkciji.
English: Based on the preclinical studies, the bulk of the administered dose is eliminated in faeces.
Slovenian: Glede na rezultate predkliničnih študij se večina danega odmerka izloči z blatom.
English: Bedaquiline has not been studied in patients with severe hepatic impairment (see section 4.2).
Slovenian: Uporabe bedakilina pri bolnikih s hudo okvaro jeter niso proučevali (glejte poglavje 4.2).
English: In female rats, there was no effect on mating or fertility with bedaquiline treatment, however some effects were observed in male rats (see section 5.3).
Slovenian: Pri podganjih samicah uporaba bedakilina ni vplivala na parjenje in plodnost, pri podganjih samcih pa so opažali določene učinke (glejte poglavje 5.3).
English: There are no clinical data on the use of SIRTURO as part of combination regimens used to treat drug-susceptible Mycobacterium tuberculosis.
Slovenian: Ni kliničnih podatkov o uporabi zdravila SIRTURO v kombinirani shemi zdravljenja okužbe z Mycobacterium tuberculosis, ki je občutljiva na zdravila.
English: In an interaction study of bedaquiline and ketoconazole, a greater effect on QTc was observed after repeated dosing with bedaquiline and ketoconazole in combination than after repeated dosing with the individual medicinal products.
Slovenian: V študiji medsebojnega delovanja bedakilina in ketokonazola so pri večkratnem odmerjanju kombinacije obeh zdravil opažali večji vpliv na interval QTc kot pri večkratnih odmerkih vsakega od zdravil posebej.
English: • infections due to mycobacterial species other than Mycobacterium tuberculosis
Slovenian: • okužb z drugimi mikobakterijami (razen Mycobacterium tuberculosis)
English: There is no experience with the treatment of acute overdose with SIRTURO.
Slovenian: Z zdravljenjem v primeru akutnega prevelikega odmerjanja zdravila SIRTURO ni na voljo nobenih izkušenj.
English: • Weeks 1-2: 400 mg (4 tablets of 100 mg) once daily
Slovenian: • 1. in 2. teden: 400 mg (4 tablete po 100 mg) enkrat na dan
English: • you have a personal or family history of a heart problem called “congenital long QT syndrome”;
Slovenian: • če imate sami ali ima kdo v vaši družini motnjo v delovanju srca, ki se imenuje "sindrom prirojenega podaljšanja intervala QT"
English: In an open label Phase IIb trial, mean increases in QTcF were larger in the 17 subjects who were using concomitant clofazimine at week 24 (mean change from reference of 31.9 ms) than in subjects who were not using concomitant clofazimine at week 24 (mean change from reference of 12.3 ms) (see section 4.4).
Slovenian: V odprti študiji faze IIb je bilo po 24 tednih zdravljenja povprečno podaljšanje intervala QTcF bolj izrazito pri 17 bolnikih, ki so sočasno uporabljali klofazimin, (s povprečno spremembo od referenčne vrednosti za 31,9 ms) kot pri bolnikih, ki niso sočasno uporabljali klofazimina (s povprečno spremembo od referenčne vrednosti za 12,3 ms) (glejte poglavje 4.4).
English: What SIRTURO looks like and contents of the pack Uncoated, white to almost white round biconvex tablet, 11 mm in diameter, with debossing of "T" over "207" on one side and "100" on the other side.
Slovenian: Izgled zdravila SIRTURO in vsebina pakiranja Neobložena, bela do umazano bela okrogla bikonveksna tableta premera 11 mm z vtisnjeno oznako "T" preko oznake "207" na eni strani tablete in z oznako "100" na drugi strani.
English: Your doctor will decide which other medicines you should take with SIRTURO.
Slovenian: Katera druga zdravila morate jemati skupaj z zdravilom SIRTURO, bo določil vaš zdravnik.
English: Within the concentration range achieved with the therapeutic dose, no pharmacokinetic/pharmacodynamic relationship was observed in patients.
Slovenian: V okviru koncentracij, ki jih zdravilo doseže pri terapevtskem odmerjanju, pri bolnikih niso opažali odvisnosti med farmakokinetičnimi in farmakodinamičnimi lastnostmi zdravila.
English: Uncoated, white to almost white round biconvex tablet, 11 mm in diameter, with debossing of "T" over "207" on one side and "100" on the other side.
Slovenian: Neobložena, bela do umazano bela okrogla bikonveksna tableta premera 11 mm z vtisnjeno oznako "T" preko oznake "207" na eni strani tablete in z oznako "100" na drugi strani.
English: Twenty-four of these 24-week responders (14.7%) were considered non-responders at week 120, of which 19 patients had prematurely discontinued the trial while being culture converted and 5 patients had experienced relapse.
Slovenian: Štiriindvajset bolnikov (14,7%), ki se je odzvalo na zdravljenje po 24 tednih, so označili za neodzivne po 120. tednu zdravljenja; 19 bolnikov je zaradi konverzije kulture sputuma sodelovanje v študiji predčasno prekinilo, pri 5 bolnikih pa se je bolezen ponovila.
English: • Hypokalemia
Slovenian: • s hipokaliemijo.
English: If the benefit outweighs the risk, SIRTURO may be used with caution when co-administered with lopinavir/ritonavir.
Slovenian: Kadar korist odtehta tveganje, se zdravilo SIRTURO lahko sočasno uporablja s kombinacijo lopinavir/ritonavir, vendar je pri tem potrebna previdnost.
English: In the event that co-administration of such medicinal products with bedaquiline is necessary, clinical monitoring, including frequent electrocardiogram assessment, is recommended.
Slovenian: Če je sočasna uporaba teh zdravil z bedakilinom potrebna, je priporočeno klinično spremljanje, vključno s pogostim spremljanjem električne aktivnosti srca (elektrokardiogram).
English: • Weeks 3-24: 200 mg (2 tablets of 100 mg) three times per week (with at least 48 hours between doses).
Slovenian: • 3. do vključno 24. teden: 200 mg (2 tableti po 100 mg) trikrat na teden (med posameznimi odmerki mora biti najmanj 48 ur).
English: In the controlled Phase IIb study (C208), mean increases from baseline values in QTcF were observed from the first on-treatment assessment onwards (9.9 ms at week 1 for SIRTURO and 3.5 ms for placebo).
Slovenian: V nadzorovani študiji faze IIb (v študiji C208) so od prve ocene elektrokardiograma v času zdravljenja dalje opazili povprečno podaljšanje intervala QTcF (9,9 ms po 1 tednu zdravljenja za SIRTURO in 3,5 ms za placebo) glede na izhodiščne vrednosti.
English: QT interval prolonging medicinal products
Slovenian: Zdravila, ki podaljšujejo interval QT
English: The inhibition of ATP synthase leads to bactericidal effects for both replicating and non-replicating tubercle bacilli.
Slovenian: Zaviranje ATP-sintaze ima baktericiden učinek tako na tiste bacile tuberkuloze, ki so v fazi razmnoževanja, kot na tiste, ki niso.
English: If AST or ALT exceeds 5 times the upper limit of normal then the regimen should be reviewed and SIRTURO and/or any hepatotoxic background medicinal product should be discontinued.
Slovenian: Če koncentracija aspartat-aminotransferaze (AST) ali alanin-aminotransferaze (ALT) presega 5-kratnik zgornje meje normalnih koncentracij, je treba ponovno pregledati shemo zdravljenja in prekiniti jemanje zdravila SIRTURO in/ali katerega od osnovnih zdravil, če ta škodljivo vpliva na jetra.
English: The urinary excretion of unchanged bedaquiline was < 0.001% of the dose in clinical studies, indicating that renal clearance of unchanged active substance is insignificant.
Slovenian: V kliničnih študijah se je manj kot 0,001% odmerka bedakilina izločilo v nespremenjeni obliki z urinom, kar pomeni, da izločanje nespremenjene učinkovine preko ledvic ni pomembno.
English: During the trial, there was no evidence of antecedent significant QT prolongation or clinically significant dysrhythmia in any of the patients that died.
Slovenian: Pri nobenem od umrlih bolnikov niso v času študije opazili znakov predhodnega pomembnega podaljšanja intervala QT ali klinično pomembnih motenj ritma.
English: In a population pharmacokinetic analysis of tuberculosis patients (age range 18 years to 68 years) treated with SIRTURO age was not found to influence the pharmacokinetics of bedaquiline.
Slovenian: Po podatkih analize populacijske farmakokinetike pri bolnikih, ki imajo tuberkulozo, so stari od 18 do 68 let in prejemajo zdravilo SIRTURO, starost ne vpliva na farmakokinetiko bedakilina.
English: An in vitro study indicated a potential for bedaquiline to inhibit BCRP at the concentrations achieved in the intestine after oral administration.
Slovenian: In vitro študija je pokazala, da bi bedakilin v koncentracijah, doseženih v prebavilih po peroralnem jemanju, lahko zaviral BCRP.
English: This increase is likely due to ritonavir.
Slovenian: Verjetno je vzrok ritonavir.
English: Administration of bedaquiline with food increased the relative bioavailability by about 2-fold compared to administration under fasted conditions.
Slovenian: Odmerjanje bedakilina skupaj s hrano je povečalo njegovo biološko uporabnost približno za dvakrat v primerjavi z odmerjanjem zdravila na tešče.
English: In study C208 (stage 1 and 2), aminotransferase elevations of at least 3 x ULN developed more frequently in the SIRTURO treatment group (11/102 [10.8%] versus 6/105 [5.7%]) in the placebo treatment group.
Slovenian: V študiji C208 (1. in 2. stopnja) je do zvišanja koncentracije aminotransferaz na najmanj 3-kratnik zgornje meje normalnih vrednosti prišlo bolj pogosto v skupini z zdravilom SIRTURO (11/102 [10,8%] kot v skupini s placebom (6/105 [5,7%]).
English: SIRTURO is used to treat tuberculosis that affects the lungs when the disease has become resistant to other antibiotics.
Slovenian: Zdravilo SIRTURO uporabljamo za zdravljenje tuberkuloze, ki prizadene pljuča in je odporna na druge antibiotike, kar imenujemo tuberkuloza, odporna proti več zdravilom.
English: The plasma bedaquiline exposure (AUC) in rats and dogs was similar to that observed in humans.
Slovenian: Pri podganah in psih je bila izpostavljenost bedakilinu v plazmi (AUC) podobna kot pri ljudeh.
English: The short-term co-administration of bedaquiline with isoniazid/pyrazinamide in healthy subjects did not result in clinically relevant changes in the exposure (AUC) to bedaquiline, isoniazid or pyrazinamide.
Slovenian: Pri zdravih prostovoljcih kratkotrajna sočasna uporaba bedakilina z izoniazidom oziroma s pirazinamidom ni povzročila klinično pomembnih sprememb izpostavljenosti (AUC) bedakilinu ali izoniazidu oziroma pirazinamidu.
English: Co-administration of single-dose bedaquiline and multiple-dose nevirapine did not result in clinically relevant changes in the exposure to bedaquiline.
Slovenian: Pri enkratnem odmerku bedakilina in sočasnem odmerjanju več odmerkov nevirapina ni prišlo do klinično pomembnih sprememb izpostavljenosti bedakilinu.
English: In an interaction study of single-dose bedaquiline and once daily rifampicin (strong inducer) in healthy subjects, the exposure (AUC) to bedaquiline was reduced by 52% [90% CI (-57; -46)].
Slovenian: V interakcijski študiji z zdravimi prostovoljci, ki so prejeli enkraten odmerek bedakilina, rifampicin (močan induktor) pa so jim odmerjali enkrat dnevno, je bila izpostavljenost bedakilinu (AUC) zmanjšana za 52% [90-odstotni IZ (-57; -46)].
English: Medicine (name of the active substance)
Slovenian: Zdravilo (ime zdravilne učinkovine)
English: How to take SIRTURO
Slovenian: Kako jemati zdravilo SIRTURO
English: Bedaquiline had no effects on fertility when evaluated in female rats.
Slovenian: Bedakilin pri testiranju na podganjih samicah ni vplival na plodnost.
English: During the investigational phase in Stage 2 of study C208, increased aminotransferases were reported in 7/79 (8.9%) patients in the SIRTURO treatment group compared to 1/81 (1.2%) in the placebo treatment group.
Slovenian: V 2.stopnji študije C208 so poročali o povečanju koncentracij aminotransferaz pri 7/79 (8,9%) bolnikih v skupini, ki je prejemala zdravilo SIRTURO, v primerjavi z 1/81 (1,2%) bolnikom v skupini, ki je prejemala placebo.
English: • There must be at least 48 hours in between each time you take SIRTURO.
Slovenian: • Med dvema odmerjanjema zdravila SIRTURO mora preteči najmanj 48 ur.
English: Mortality
Slovenian: Umrljivost
English: The plasma protein binding of bedaquiline is > 99.9% in all species tested, including human.
Slovenian: Bedakilin se je pri vseh testiranih živalskih vrstah in pri ljudeh vezal na beljakovine v plazmi v več kot 99,9%.
English: Adverse drug reactions to SIRTURO reported from controlled trials in 102 patients treated with SIRTURO are presented in the table below.
Slovenian: V spodnji preglednici so prikazani neželeni učinki zdravila SIRTURO, o katerih so poročali v nadzorovanih kliničnih študijah pri 102 bolnikih, ki so prejemali zdravilo SIRTURO.
English: Conversion rates at week 24 were highest (87.1%; 81/93) in patients with MDRH&R-TB, 77.3% (34/44) in pre-XDR-TB patients and lowest (54.1%; 20/37) in XDR-TB patients.
Slovenian: Po 24 tednih zdravljenja je bila pogostnost konverzij največja (87,1%; 81/93) pri bolnikih z MDRH&R-TB, 77,3% (34/44) pri bolnikih s pre-XDR-TB in najmanjša (54,1%; 20/37) pri bolnikih z XDR-TB.
English: Co-administration of bedaquiline and moderate or strong CYP3A4 inducers used systemically should, therefore, be avoided (see section 4.5).
Slovenian: Zato se je treba izogibati sočasni uporabi bedakilina in zmernih ali močnih induktorjev encima CYP3A4 s sistemskim vnosom (glejte poglavje 4.5).
English: SIRTURO 100 mg tablets bedaquiline
Slovenian: SIRTURO 100 mg tablete bedakilin
English: If you take more SIRTURO than you should, talk to a doctor straight away.
Slovenian: Če ste vzeli večji odmerek zdravila SIRTURO, kot bi smeli Če ste vzeli večji odmerek zdravila SIRTURO, kot bi smeli, se takoj posvetujte z zdravnikom.
English: SIRTURO contains “lactose” (a type of sugar).
Slovenian: Zdravilo SIRTURO vsebuje laktozo monohidrat Zdravilo SIRTURO vsebuje "laktozo" (vrsto sladkorja).
English: Bedaquiline was a weak OCT1, OATP1B1 and OATP1B3 substrate in vitro, while M2 was not.
Slovenian: Bedakilin je bil in vitro šibek substrat OCT1, OATP1B1 in OATP1B3, M2 pa ne. Bedakilin in vitro ni bil substrat za MRP2 in BCRP.
English: There are only limited clinical data on the efficacy of bedaquiline in HIV-infected patients not receiving antiretroviral (ARV) therapy.
Slovenian: Klinični podatki o učinkovitosti bedakilina pri bolnikih, okuženih s HIV, ki se ne zdravijo s protiretrovirusnimi zdravili so omejeni.
English: Consideration should be given to WHO guidelines when selecting the appropriate combination regimen.
Slovenian: Pri izbiri ustreznega kombiniranega režima zdravljenja je treba upoštevati smernice Svetovne zdravstvene organizacije (SZO).
English: Multi-drug resistant Mycobacterium tuberculosis (MDRH&R-TB): isolate resistant to at least isoniazid and rifampicin, but susceptible to fluoroquinolones and second line injectable agents.
Slovenian: Proti več zdravilom odporna Mycobacterium tuberculosis (MDRH&R-TB): izolat, odporen najmanj na izoniazid in rifampicin, vendar občutljiv na fluorokinolone in učinkovine drugega reda za injiciranje.
English: In the randomised phase IIb study (C208, stage 2) a higher rate of deaths was seen in the SIRTURO treatment group (12.7%; 10/79 patients) compared to the placebo treatment group (3.7%; 3/81 patients).
Slovenian: V randomizirani študiji faze IIb (C208, 2. stopnje) so v skupini, ki je prejemala zdravilo SIRTURO (12,7%; 10/79 bolnikov) opazili večjo stopnjo smrti, kot v skupini, ki je prejemala placebo (3,7%; 3/81 bolnikov).
English: Bedaquiline is metabolised by CYP3A4.
Slovenian: Bedakilin se presnavlja z encimom CYP3A4.
English: SIRTURO has not been studied in patients with severe hepatic impairment and is not recommended in this population.
Slovenian: Pri bolnikih s hudo okvaro jeter uporabe zdravila SIRTURO niso preučevali, zato uporabe pri tej skupini bolnikov ne priporočamo.
English: In the rat, no adverse effects were observed in a pre- and post-natal development study at maternal plasma exposure (AUC) similar to humans and exposure in the offspring 3-fold higher than in adult humans.
Slovenian: Pri podganah v študiji prenatalnega in postnatalnega razvoja niso opažali neželenih učinkov pri izpostavljenosti zdravilu v plazmi, ki je bila pri podganjih samicah podobna kot pri ljudeh, pri mladičih pa je bila 3-krat večja kot pri odraslem človeku.
English: Of the 42 patients who were non-responders at week 24, confirmed culture conversion after week 24 (i.e., after bedaquiline dosing ended but the background regimen was continued) occurred in 9 patients (21.4%) and was maintained at week 120.
Slovenian: Od 42 neodzivnih bolnikov po 24. tednu so pri 9 bolnikih (21,4%) potrdili konverzijo kulture sputuma (po zaključku odmerjanja bedakilina so nadaljevali z osnovno shemo zdravljenja), ki je trajala do 120. tedna.
English: The largest mean increase from baseline values in QTcF during the 24 weeks of SIRTURO treatment was 15.7 ms (at week 18).
Slovenian: V 24-tedenskem obdobju zdravljenja z zdravilom SIRTURO je največje povprečno podaljšanje intervala QTcF, glede na izhodiščno vrednost, znašalo 15,7 ms (po 18 tednih).
English: Serum potassium, calcium, and magnesium should be obtained at baseline and corrected if abnormal.
Slovenian: Pred začetkom zdravljenja je potrebno preveriti koncentracije kalija, kalcija in magnezija v serumu in jih popraviti, če niso znotraj normalnih vrednosti.
English: The corresponding plasma exposure (AUC) was 2-fold higher in rats compared to humans.
Slovenian: Pri podganah je ustrezna izpostavljenost zdravilu v plazmi (AUC) dvakrat večja kot pri ljudeh.
English: The short-term co-administration of bedaquiline and ketoconazole (potent CYP3A4 inhibitor) in healthy subjects increased the exposure (AUC) to bedaquiline by 22% [90% CI (12; 32)].
Slovenian: Kratkotrajno sočasno odmerjanje bedakilina in ketokonazola (močan CYP3A4 zaviralec) je pri zdravih prostovoljcih povečalo izpostavljenost bedakilinu (AUC) za 22% [90-odstotni IZ (12; 32)].
English: Bedaquiline has activity against Mycobacterium tuberculosis with a minimal inhibitory concentration (MIC) for drug-sensitive as well as drug-resistant strains (multi-drug resistant including preextensively drug resistant strains, extensively drug resistant strains) in the range of ≤ 0.008-0.12 mg/l.
Slovenian: Bedakilin deluje proti bakteriji Mycobacterium tuberculosis z minimalno inhibitorno koncentracijo (MIK) za občutljive in za odporne seve (odporne proti več zdravilom, kar vključuje predstopnjo izredno odpornih sevov (pre-XDR-pre-extensively drug resistant) in izredno odporne seve (XDR
English: After reaching Cmax, bedaquiline concentrations decline tri-exponentially.
Slovenian: Ko bedakilin doseže Cmax, začne njegova koncentracija upadati trieksponentno.
English: • Final analysis - Clinical Study Report 4Q 2023
Slovenian: • Končna analiza podatkovklinično poročilo 4. četrtletje
English: General measures to support basic vital functions including monitoring of vital signs and electrocardiogram (QT interval) monitoring should be taken in case of deliberate or accidental overdose.
Slovenian: V primeru namernega ali nenamernega prevelikega odmerjanja je treba uvesti splošne ukrepe za podporo vitalnih funkcij, kar vključuje spremljanje življenjskih znakov in elektrokardiografijo (meritev trajanja intervala QT).
English: An additive or synergistic effect on QT prolongation of bedaquiline when co-administered with other medicinal products that prolong the QT interval cannot be excluded and frequent monitoring is recommended (see section 4.4).
Slovenian: Pri sočasni uporabi bedakilina in drugih zdravil, ki podaljšujejo interval QT, ni mogoče izključiti možnosti njihovega aditivnega ali sinergističnega delovanja, priporočeno je pogosto spremljanje (glejte poglavje 4.4).
English: Exposure to bedaquiline was lower in multi-drug resistant tuberculosis-infected patients than in healthy subjects.
Slovenian: Pri bolnikih s tuberkulozo, odporno na več zdravil je bila izpostavljenost bedakilinu manjša kot pri zdravih osebah.
English: In the event that co-administration of clofazimine with bedaquiline is necessary, clinical monitoring, including frequent electrocardiogram assessment, is recommended (see section 4.5).
Slovenian: Če je potrebna sočasna uporaba klofazimina in bedakilina je priporočeno klinično spremljanje, vključno s pogostim spremljanjem električne aktivnosti srca (elektrokardiogram) (glejte poglavje 4.5).